Seeking Alpha

New Glaxo, Theravance COPD drug carries strong warning

  • "The warning on the drug's label is one of the strongest issued by the regulator," Reuters says, referring to the FDA's mention of an increase in the risk of asthma-related death with GlaxoSmithKline (GSK +0.2%) and Theravance's (THRX -1.5%) Anoro Ellipta.
  • The risk stems from vilanterol, the drug's LABA component.
  • The COPD treatment won FDA approval on Wednesday.
  • Analysts see annual sales hitting ~$2.65B by 2018, Reuters notes.
  • FDA release
Comments (1)
  • This is no different that other LABA/ICS drugs that fall into the same class. The point is to make everyone aware to keep patients safe.
    22 Dec 2013, 12:02 PM Reply Like
DJIA (DIA) S&P 500 (SPY)